A recent study published in Science makes the case for a class effect of COX-2 inhibitors on heart disease. We have argued that the other, “safe,” COX-2 drugs weren’t out of the woods, after Merck pulled Vioxx from the marketplace. Now, a study details the mechanism linking COX-2 and heart disease. We look at the implications.
